Phase 2 Cardiomyopathy Trial, Recruiting NCT07218887 Sponsor: Alexion Pharmaceuticals, Inc. Condition: Cardiomyopathy
Back to Cardiomyopathy

Phase 2 Cardiomyopathy Trial, Recruiting

NCT07218887
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have a specific gene change (mutation) in a gene called BAG3 that is known or likely to cause health problems
  • You have been diagnosed with a type of heart condition called dilated cardiomyopathy (DCM), where the heart is enlarged and does not pump well
  • You are on a stable combination of standard medications for heart failure
  • Your heart can be clearly seen using an ultrasound scan (echocardiography)

Who may not be able to join:

  • Your body has already developed immune defenses (antibodies) against a substance called AAV9, which is used to deliver the treatment
  • You have a harmful gene change in a different gene (other than BAG3) that is also a recognised cause of dilated cardiomyopathy
  • Your heart failure is currently unstable or has recently gotten significantly worse (known as decompensated heart failure)

Important: Always verify eligibility with the trial site directly before applying.

Note: This list may not cover all eligibility requirements. Additional criteria may apply that are not listed here — please confirm all details with the trial site.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 1-855-752-2356

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Alexion Pharmaceuticals, Inc.
Registry
ClinicalTrials.gov
Start date
24 October 2025
Est. completion
27 January 2032

Where this trial is recruiting

🇮🇹 Italy 🇪🇸 Spain 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov